Brain Regeneration
Research

The primary objective of the NTBII Foundation is to raise funds and direct them towards the most promising and scientifically backed biomedical therapeutics for brain regeneration research.

NTBII aims to spark clinical trials by endorsing programmatic research involving joint collaborations between research institutions, private biotech companies, patients, and their families. The Foundation plans to partner with the FDA to obtain approval for N-of-1 therapies, which are genomically targeted and customized to suit an individual's brain injury.

N-of-1 therapies are treatment approaches that are genomically targeted and customized to suit an individual's specific brain injury. This approach represents the forefront of personalized medicine.

In the long run, the Foundation aspires to make a wider spectrum of biomedical therapies accessible to the vast number of individuals affected by moderate and severe brain injuries.

NTBII strives for significant advancements that could potentially enhance the quality of life for individuals impacted by brain injuries. The Foundation seeks to engage in research partnerships that contribute towards the broader scientific community's endeavors and ultimately aid those suffering from brain injury and their loved ones.

The NTBII Foundation aims to bridge the gap between scientific research and actual patient benefit by sparking clinical trials, pushing for regulatory approvals, and fostering collaborations that can expedite the journey from lab to clinic.

The NTBII Foundation follows a multi-faceted approach which includes raising funds for research, endorsing collaborative programmatic research, and pushing for FDA approvals for innovative treatment methods like N-of-1 therapies.

The Foundation is guided by a board of distinguished researchers and leaders in the biotech industry. This ensures the scientific rigor and promise of the biomedical therapeutics that they fund and advocate.